BIOMAT Database Logo BIOMAT Database Logo

Discontinuation of Conventional Synthetic Disease-Modifying Antirheumatic Drugs in Patients With Rheumatoid Arthritis and Excellent Disease Control. 2023

Siri Lillegraven, and Nina Paulshus Sundlisæter, and Anna-Birgitte Aga, and Joseph Sexton, and Daniel H Solomon, and Désirée van der Heijde, and Espen A Haavardsholm
Center for Treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway.

UI MeSH Term Description Entries
D008727 Methotrexate An antineoplastic antimetabolite with immunosuppressant properties. It is an inhibitor of TETRAHYDROFOLATE DEHYDROGENASE and prevents the formation of tetrahydrofolate, necessary for synthesis of thymidylate, an essential component of DNA. Amethopterin,Methotrexate Hydrate,Methotrexate Sodium,Methotrexate, (D)-Isomer,Methotrexate, (DL)-Isomer,Methotrexate, Dicesium Salt,Methotrexate, Disodium Salt,Methotrexate, Sodium Salt,Mexate,Dicesium Salt Methotrexate,Hydrate, Methotrexate,Sodium, Methotrexate
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D001172 Arthritis, Rheumatoid A chronic systemic disease, primarily of the joints, marked by inflammatory changes in the synovial membranes and articular structures, widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, and by atrophy and rarefaction of bony structures. Etiology is unknown, but autoimmune mechanisms have been implicated. Rheumatoid Arthritis
D001688 Biological Products Complex pharmaceutical substances, preparations, or matter derived from organisms usually obtained by biological methods or assay. Biologic,Biologic Drug,Biologic Product,Biological,Biological Drug,Biological Medicine,Biological Product,Biologics,Biopharmaceutical,Natural Product,Natural Products,Biologic Drugs,Biologic Medicines,Biologic Pharmaceuticals,Biologic Products,Biological Drugs,Biological Medicines,Biologicals,Biopharmaceuticals,Products, Biological,Drug, Biologic,Drug, Biological,Drugs, Biologic,Drugs, Biological,Medicine, Biological,Medicines, Biologic,Medicines, Biological,Pharmaceuticals, Biologic,Product, Biologic,Product, Biological,Product, Natural
D016896 Treatment Outcome Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series. Rehabilitation Outcome,Treatment Effectiveness,Clinical Effectiveness,Clinical Efficacy,Patient-Relevant Outcome,Treatment Efficacy,Effectiveness, Clinical,Effectiveness, Treatment,Efficacy, Clinical,Efficacy, Treatment,Outcome, Patient-Relevant,Outcome, Rehabilitation,Outcome, Treatment,Outcomes, Patient-Relevant,Patient Relevant Outcome,Patient-Relevant Outcomes
D018501 Antirheumatic Agents Drugs that are used to treat RHEUMATOID ARTHRITIS. Anti-Rheumatic Agent,Anti-Rheumatic Drug,Antirheumatic Agent,Antirheumatic Disease-Modifying Second-Line Drug,Antirheumatic Drug,DMARD,Disease-Modifying Antirheumatic Drug,Disease-Modifying Antirheumatic Drugs,Anti-Rheumatic Agents,Anti-Rheumatic Agents, Non-Steroidal,Anti-Rheumatic Drugs,Antirheumatic Disease-Modifying Second-Line Drugs,Antirheumatic Drugs,Antirheumatic Drugs, Disease-Modifying,Disease-Modifying, Antirheumatic Second-Line Drugs,Agent, Anti-Rheumatic,Agent, Antirheumatic,Anti Rheumatic Agent,Anti Rheumatic Agents,Anti Rheumatic Agents, Non Steroidal,Anti Rheumatic Drug,Anti Rheumatic Drugs,Antirheumatic Disease Modifying Second Line Drug,Antirheumatic Disease Modifying Second Line Drugs,Antirheumatic Drug, Disease-Modifying,Antirheumatic Drugs, Disease Modifying,Disease Modifying Antirheumatic Drug,Disease Modifying Antirheumatic Drugs,Disease Modifying, Antirheumatic Second Line Drugs,Drug, Anti-Rheumatic,Drug, Antirheumatic,Drug, Disease-Modifying Antirheumatic,Non-Steroidal Anti-Rheumatic Agents
D028761 Withholding Treatment Withholding or withdrawal of a particular treatment or treatments, often (but not necessarily) life-prolonging treatment, from a patient or from a research subject as part of a research protocol. The concept is differentiated from REFUSAL TO TREAT, where the emphasis is on the health professional's or health facility's refusal to treat a patient or group of patients when the patient or the patient's representative requests treatment. Withholding of life-prolonging treatment is usually indexed only with EUTHANASIA, PASSIVE, unless the distinction between withholding and withdrawing treatment, or the issue of withholding palliative rather than curative treatment, is discussed. Withdrawing Care,Cessation of Treatment,Withdrawing Treatment,Care, Withdrawing,Treatment Cessation,Treatment Cessations,Treatment, Withdrawing,Treatment, Withholding,Treatments, Withdrawing,Treatments, Withholding,Withdrawing Treatments,Withholding Treatments

Related Publications

Siri Lillegraven, and Nina Paulshus Sundlisæter, and Anna-Birgitte Aga, and Joseph Sexton, and Daniel H Solomon, and Désirée van der Heijde, and Espen A Haavardsholm
Half-Dose vs Stable-Dose Conventional Synthetic Disease-Modifying Antirheumatic Drugs and Disease Flare in Patients With Rheumatoid Arthritis.
September 2021, JAMA,
Siri Lillegraven, and Nina Paulshus Sundlisæter, and Anna-Birgitte Aga, and Joseph Sexton, and Daniel H Solomon, and Désirée van der Heijde, and Espen A Haavardsholm
Effects of Conventional Synthetic Disease-Modifying Antirheumatic Drugs on Response to Periodontal Treatment in Patients with Rheumatoid Arthritis.
January 2018, BioMed research international,
Siri Lillegraven, and Nina Paulshus Sundlisæter, and Anna-Birgitte Aga, and Joseph Sexton, and Daniel H Solomon, and Désirée van der Heijde, and Espen A Haavardsholm
Pneumonia vaccination timing in relation to starting conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis.
December 2020, Annals of the rheumatic diseases,
Siri Lillegraven, and Nina Paulshus Sundlisæter, and Anna-Birgitte Aga, and Joseph Sexton, and Daniel H Solomon, and Désirée van der Heijde, and Espen A Haavardsholm
Rheumatoid arthritis: disease-modifying antirheumatic drugs.
December 1983, Clinics in rheumatic diseases,
Siri Lillegraven, and Nina Paulshus Sundlisæter, and Anna-Birgitte Aga, and Joseph Sexton, and Daniel H Solomon, and Désirée van der Heijde, and Espen A Haavardsholm
Leflunomide combined with conventional disease-modifying antirheumatic drugs or biologics in patients with rheumatoid arthritis.
December 2006, Joint bone spine,
Siri Lillegraven, and Nina Paulshus Sundlisæter, and Anna-Birgitte Aga, and Joseph Sexton, and Daniel H Solomon, and Désirée van der Heijde, and Espen A Haavardsholm
Successful discontinuation of biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis in real-world settings.
July 2021, Modern rheumatology,
Siri Lillegraven, and Nina Paulshus Sundlisæter, and Anna-Birgitte Aga, and Joseph Sexton, and Daniel H Solomon, and Désirée van der Heijde, and Espen A Haavardsholm
The perioperative use of synthetic and biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis.
January 2017, Swiss medical weekly,
Siri Lillegraven, and Nina Paulshus Sundlisæter, and Anna-Birgitte Aga, and Joseph Sexton, and Daniel H Solomon, and Désirée van der Heijde, and Espen A Haavardsholm
Conventional disease-modifying antirheumatic drugs in early arthritis.
November 2005, Rheumatic diseases clinics of North America,
Siri Lillegraven, and Nina Paulshus Sundlisæter, and Anna-Birgitte Aga, and Joseph Sexton, and Daniel H Solomon, and Désirée van der Heijde, and Espen A Haavardsholm
Factors associated with discontinuation of glucocorticoids after starting biological disease-modifying antirheumatic drugs in rheumatoid arthritis patients.
January 2020, Modern rheumatology,
Siri Lillegraven, and Nina Paulshus Sundlisæter, and Anna-Birgitte Aga, and Joseph Sexton, and Daniel H Solomon, and Désirée van der Heijde, and Espen A Haavardsholm
Treatment failure with disease-modifying antirheumatic drugs in rheumatoid arthritis patients.
August 2012, Singapore medical journal,
Copied contents to your clipboard!